80 related articles for article (PubMed ID: 22636603)
1. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
[TBL] [Abstract][Full Text] [Related]
2. Multiple Primary Melanoma Associated with CDKN2A Mutation-Case Report and Review of the Literature.
Nurla LA; Aşchie M; Cozaru GC; Boșoteanu M
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792946
[TBL] [Abstract][Full Text] [Related]
3. Genetic predisposition to pancreatic cancer.
Ghiorzo P
World J Gastroenterol; 2014 Aug; 20(31):10778-89. PubMed ID: 25152581
[TBL] [Abstract][Full Text] [Related]
4. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment.
Hall MJ; Dignam JJ; Olopade OI
J Genet Couns; 2008 Aug; 17(4):365-72. PubMed ID: 18581219
[TBL] [Abstract][Full Text] [Related]
5. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
Zogopoulos G; Haimi I; Sanoba SA; Everett JN; Wang Y; Katona BW; Farrell JJ; Grossberg AJ; Paiella S; Klute KA; Bi Y; Wallace MB; Kwon RS; Stoffel EM; Wadlow RC; Sussman DA; Merchant NB; Permuth JB; Golan T; Raitses-Gurevich M; Lowy AM; Liau J; Jeter JM; Lindberg JM; Chung DC; Earl J; Brentnall TA; Schrader KA; Kaul V; Huang C; Chandarana H; Smerdon C; Graff JJ; Kastrinos F; Kupfer SS; Lucas AL; Sears RC; Brand RE; Parmigiani G; Simeone DM;
J Natl Compr Canc Netw; 2024 Apr; 22(3):158-166. PubMed ID: 38626807
[TBL] [Abstract][Full Text] [Related]
6. P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial Melanoma.
Nurla LA; Gheorghe E; Aşchie M; Cozaru GC; Orășanu CI; Boşoteanu M
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667459
[TBL] [Abstract][Full Text] [Related]
7. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years.
Bartsch DK; Matthäi E; Mintziras I; Bauer C; Figiel J; Sina-Boemers M; Gress TM; Langer P; Slater EP
Dtsch Arztebl Int; 2021 Mar; 118(10):163-8. PubMed ID: 33531114
[TBL] [Abstract][Full Text] [Related]
8. Surgical aspects related to hereditary pancreatic cancer.
Maurer E; Bartsch DK
Fam Cancer; 2024 Apr; ():. PubMed ID: 38662263
[TBL] [Abstract][Full Text] [Related]
9.
Maas EJ; DeBortoli E; Nathan V; Freeman NP; Mothershaw A; Smit DJ; Betz-Stablein B; Aoude LG; Stark MS; Sturm RA; Soyer HP; McInerney-Leo AM
J Med Genet; 2024 May; ():. PubMed ID: 38724174
[No Abstract] [Full Text] [Related]
10. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals.
Archibugi L; Casciani F; Carrara S; Secchettin E; Falconi M; Capurso G; Paiella S
Fam Cancer; 2024 Mar; ():. PubMed ID: 38493228
[TBL] [Abstract][Full Text] [Related]
11. The odyssee from surveillance to the detection of pancreatic cancer, total pancreatectomy, and its impact on life. insights from a p16-Leiden pathogenic variant carrier.
Spruitenburg AM; Vasen HF
Fam Cancer; 2024 Apr; ():. PubMed ID: 38662261
[No Abstract] [Full Text] [Related]
12. The genetics of melanoma: recent advances.
Hill VK; Gartner JJ; Samuels Y; Goldstein AM
Annu Rev Genomics Hum Genet; 2013; 14():257-79. PubMed ID: 23875803
[TBL] [Abstract][Full Text] [Related]
13. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.
Stefanoudakis D; Frountzas M; Schizas D; Michalopoulos NV; Drakaki A; Toutouzas KG
Curr Issues Mol Biol; 2024 Mar; 46(4):2827-2844. PubMed ID: 38666907
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic reticulum stress regulators exhibit different prognostic, therapeutic and immune landscapes in pancreatic adenocarcinoma.
Liu S; He K; Yang L; Xu F; Cui X; Qu L; Li X; Ren BC
J Cell Mol Med; 2024 Feb; 28(5):e18092. PubMed ID: 38303549
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors.
Xue L; Tang W; Zhou J; Xue J; Li Q; Ge X; Lin F; Zhao W; Guo Y
Front Oncol; 2023; 13():1276009. PubMed ID: 37936609
[TBL] [Abstract][Full Text] [Related]
16. Detection of somatic copy number deletion of the
Tian Y; Zhou J; Qiao J; Liu Z; Gu L; Zhang B; Lu Y; Xing R; Deng D
Front Oncol; 2022; 12():1038380. PubMed ID: 36531022
[TBL] [Abstract][Full Text] [Related]
17. Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.
Dalmasso B; Puccini A; Catalano F; Borea R; Iaia ML; Bruno W; Fornarini G; Sciallero S; Rebuzzi SE; Ghiorzo P
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563100
[TBL] [Abstract][Full Text] [Related]
18. Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.
Jeong AR; Forbes K; Orosco RK; Cohen EEW
J Otolaryngol Head Neck Surg; 2022 Feb; 51(1):5. PubMed ID: 35123577
[TBL] [Abstract][Full Text] [Related]
19.
Qiao J; Tian Y; Cheng X; Liu Z; Zhou J; Gu L; Zhang B; Zhang L; Ji J; Xing R; Deng D
Front Oncol; 2021; 11():801219. PubMed ID: 35004325
[TBL] [Abstract][Full Text] [Related]
20. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
Kimura H; Klein AP; Hruban RH; Roberts NJ
Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
